The Increasing Importance of Biomarkers in Clinical Trials

REUTERS/John Javellana

Developments in Clinical Trials is the latest report in the Pharma Matters series by Thomson Reuters offering expert reviews of trends and developments that shape the clinical landscape. This quarter’s Developments in Clinical Trials focuses on the increasing importance of biomarkers in clinical trials. Emerging biomarkers are explored as they relate to multiple disease predictions and their progression, drug creation, treatment protocols, as well as safety and efficacy. The report also looks at two recent conferences analyzing two significant developments:

  • The first clinical trial for rituximab/hualuronidase, testing this product in patients with non-Hodgkin’s lymphoma.
  • A case report of the first fully documented functional cure of an HIV infected infant with very early antiretroviral therapy.

Download the latest Developments in Clinical Trials report based on the strategic data and insights from Thomson Reuters Cortellis™ Clinical Trials Intelligence.

Share on LinkedInTweet about this on TwitterShare on Google+Share on FacebookShare on RedditDigg thisEmail this to someone


Leave a comment

You must be logged in to post a comment.